Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 May;65(5):775-86.
doi: 10.1111/j.1365-2125.2007.03072.x. Epub 2008 Feb 14.

Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom

Thomas M MacDonald  1 , Steven V Morant
Affiliations
Comparative Study

Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom

Thomas M MacDonald et al. Br J Clin Pharmacol. 2008 May.

Abstract

What is already known about this subject: The 1998 and 2003 Health Survey for England revealed a high prevalence of hypertension and hypercholesterolaemia in the population of England. Major changes in the reimbursement of primary care for the management of both hypertension and hypercholesterolaemia have occurred in the UK.

What this study adds: Using a GP database we have examined the proportion of subjects diagnosed and treated for hypertension and hypercholesterolaemia over time. To examine the true population rates and primary care data we compared the results of the Health survey for England in both 1998 and 2003 with the recorded data on GP computers. Despite current guidelines, many patients with hypertension and/or hypercholesterolaemia are under-treated and, even amongst those who are treated, many do not achieve their blood pressure and/or lipid targets. Although treatment rates in the UK have improved recently, particularly for lipid-lowering therapies, they remain suboptimal. AIMS To determine the prevalence and treatment of hypertension, dyslipidaemia and both together in the UK between 1998 and 2006.

Methods: We used The Health Improvement Network (THIN) a general practice-based database from 1998 to 2006 and we compared the 1998 and 2003 data to that taken from the Health Survey for England (HSE) in 1998 and 2003.

Results: The prevalence (treatment) of hypertension was 25.3% (11.4%) in 1998, 27.8% (15.1%) in 2003 and 26.9% (16.2%) in 2006 in THIN. In HSE it was 37.3% (9.6%) in 1998 and 32.9% (13.8%) in 2003. For dyslipidaemia the figures were 8.6% (1.9%), 18.5% (6.5%) and 24.4% (9.8%) for THIN and 67.8% (2.3%) and 74.9% (7.0%) for HSE. Concurrent hypertension and dyslipidaemia in THIN increased from 5.5% (1.1%) in 1998 to 13.5% (4.5%) in 2003 and 17.4% (7.1%) in 2006. The prevalence of both conditions was 30.6% (0.7%) in HSE in 1998 and 28.7% (3.1%) in 2003.

Conclusions: There has been a progressive improvement in the detection and treatment of hypertension, dyslipidaemia and both conditions together between 1998 and 2006. However, much still needs to be done to improve the diagnosis and treatment of hypertension, hypercholesterolaemia and concurrent hypertension and hypercholesterolaemia in the United Kingdom.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of diagnosis (A) and treatment (B) for hypertension in the HSE (solid lines) and THIN (dashed lines) in 1998 (red), 2003 (blue) and 2006 (green)
Figure 2
Figure 2
Prevalence of diagnosis (A) and treatment (B) for hypercholesterolaemia in the HSE (solid lines) and THIN (dashed lines) in 1998 (red), 2003 (blue) and 2006 (green)
Figure 3
Figure 3
Prevalence of diagnosis (A) and treatment (B) for concurrent hypertension and hypercholesterolaemia in the HSE (solid lines) and THIN (dashed lines) in 1998 (red), 2003 (blue) and 2006 (green)
See this image and copyright information in PMC

References

    1. Rayner M, Peterson S for the British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics. 2000. Oxford: British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford, Institute of Health Sciences; 2000.
    1. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601–10. - PubMed
    1. Poulter N. Global risk of cardiovascular disease. Heart. 2003;89(Suppl. 2):ii2–5. discussion ii35–7. - PMC - PubMed
    1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–60. - PubMed
    1. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(1 Pt 2):3S–10S. - PubMed

Publication types

Substances